← Leaderboards
Adam L Cohen
University Of Utah
$179,645
Attributed
$359,290
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $198.7K · FY2018–19$200K$150K$100K$50K$0
'18
'19
Funding mix
By agency
NIH$359,290 · 1
By mechanism
R21$359,290 · 1
Top collaborators
- Alana L Welm2 shared
Most similar at University Of Utah
Same institution · by research overlap
- Bryan E. Welm$3,719,219
- Dennis L Parker$23,150,321
- Kenneth Michael Boucher$3,199,164
- Peter J Stang$4,578,295
- Xuli Wang$1,536,600
Others in their field
Other Emerging Leaders on “Antibodies”
- Bambra Strokes · Ppd Development Lp$461,655,950
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$169,304,044
- Yunda Huang · Fred Hutchinson Cancer Center$73,421,550
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Hanjoon Ryu$28,519,898
- Wendy Sammons-Jackson · National Institute Of Allergy And Infectious Diseases$27,369,420
Research focus
AntibodiesBisphosphonateBloodBoneBone LossBone PainBone RemodelingBone TurnoverBreast Cancer ModelBreast Cancer PatientBreast Cancer TherapyCancer PatientCellsCharacteristicsClinical InvestigationClinical TrialsDetectionDoseExhibitsFirst-In-HumanFractureGeneticHypercalcemiaAftercare
Grant awards (2)
An Exploratory Phase 1B Study to Assess the Effects of Merestinib on Bone Metastases in Subjects with Metastatic Breast Cancer$160,604
R21 · FY2019 · CA
An Exploratory Phase 1B Study to Assess the Effects of Merestinib on Bone Metastases in Subjects with Metastatic Breast Cancer$198,686
R21 · FY2018 · CA